" class="no-js "lang="en-US"> The Hepatitis C Trust - Medtech Alert
Thursday, October 03, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
The Hepatitis C Trust | Pharmtech Focus

The Hepatitis C Trust

About The Hepatitis C Trust

The Hepatitis C Trust

The Hepatitis C Trust is the national UK charity for hepatitis C with offices in London and Falkirk. It has been operating since 2001. It is a patient-led and patient-run organisation: most of our board, staff, and volunteers have had hepatitis C and have cleared it after treatment.

Related Story

Diseases

 New NHS Programme to Find and Cure Hidden Hepatitis C | Pharmtech Focus

New NHS Programme to Find and Cure Hidden Hepatitis C

August 1 2022

Thousands more people will get potentially life-saving treatment for Hepatitis C thanks to a new […]